Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx228
Abstract: Background In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored… read more here.
Keywords: chemotherapy; platinum; bevacizumab; aurelia trial ... See more keywords